Literature DB >> 11310387

Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.

N J Gogtay1, S Desai, V S Kadam, K D Kamtekar, S S Dalvi, N A Kshirsagar.   

Abstract

OBJECTIVES: To analyze the relapse pattern of Plasmodium vivax in the city of Mumbai.
METHODS: 283 cases of smear positive vivax malaria were treated with full dose (25 mg/kg) chloroquine and were asked to follow up for at least one year. None of the patients received primaquine.
RESULTS: Of the 150 cases who followed up for at least one year, 19 relapsed, 17/19 relapsed within the first 6 months; indicating that the relapse pattern in the city is predominantly of the tropical or Chesson strain type.
CONCLUSIONS: Vivax malaria patients should be monitored for at least six months. Those who do relapse should receive treatment with full dose chloroquine and 14 days of primaquine treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11310387

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  9 in total

1.  RADICAL CURE OF VIVAX MALARIA : 5 OR 14 DAYS.

Authors:  K M Hassan; M K Gosh
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Entomologic and molecular investigation into Plasmodium vivax transmission in Singapore, 2009.

Authors:  Lee-Ching Ng; Kim-Sung Lee; Cheong-Huat Tan; Peng-Lim Ooi; Sai-Gek Lam-Phua; Raymond Lin; Sook-Cheng Pang; Yee-Ling Lai; Suhana Solhan; Pei-Pei Chan; Kit-Yin Wong; Swee-Tuan Ho; Indra Vythilingam
Journal:  Malar J       Date:  2010-10-29       Impact factor: 2.979

Review 3.  Determinants of relapse periodicity in Plasmodium vivax malaria.

Authors:  Nicholas J White
Journal:  Malar J       Date:  2011-10-11       Impact factor: 2.979

4.  Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.

Authors:  Jung-Ryong Kim; Amitabha Nandy; Ardhendu Kumar Maji; Manjulika Addy; Arjen M Dondorp; Nicholas P J Day; Sasithon Pukrittayakamee; Nicholas J White; Mallika Imwong
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

5.  Molecular Monitoring of Plasmodium vivax Infection after Radical Treatment in Southeastern Iran.

Authors:  M Nateghpour; S Ayazian Mavi; H Keshavarz; S Rezaei; F Abedi; Gh Edrissian; A Raeisi
Journal:  Iran J Arthropod Borne Dis       Date:  2010-06-30

6.  Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India.

Authors:  Sneh Shalini; Saumyadripta Chaudhuri; Patrick L Sutton; Neelima Mishra; Nalini Srivastava; Joseph K David; K John Ravindran; Jane M Carlton; Alex Eapen
Journal:  Malar J       Date:  2014-03-31       Impact factor: 2.979

7.  Evaluation of pharmacokinetics of single-dose chloroquine in malnourished children with malaria- a comparative study with normally nourished children.

Authors:  Prashant P Kadam; Nithya Jaideep Gogtay; Sunil Karande; V Shah; Urmila M Thatte
Journal:  Indian J Pharmacol       Date:  2016 Sep-Oct       Impact factor: 1.200

8.  Therapeutic Assessment of Primaquine for Radical Cure of Plasmodium vivax Malaria at Primary and Tertiary Care Centres in Southwestern India.

Authors:  Rishikesh Kumar; Vasudeva Guddattu; Kavitha Saravu
Journal:  Korean J Parasitol       Date:  2016-12-31       Impact factor: 1.341

9.  A study on relapse/re-infection rate of Plasmodium vivax malaria and identification of the predominant genotypes of P. vivax in two endemic districts of Nepal.

Authors:  Sulochana Manandhar; Chop L Bhusal; Umesh Ghimire; Shankar P Singh; Dibesh B Karmacharya; Sameer M Dixit
Journal:  Malar J       Date:  2013-09-16       Impact factor: 2.979

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.